Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMaría Teresa Cedena RomeroEOEnrique M. OcioYGYolanda González‐Montes

Discussion

Loading...

Member takes

Overview

This randomized trial demonstrates that dynamic PRD monitoring improves progression-free survival in multiple myeloma patients, indicating its prognostic value.

Key Points

  • To investigate the prognostic value of minimally invasive peripheral residual disease assessment in multiple myeloma patients.
  • Included 247 transplant-ineligible patients enrolled in the GEM2017FIT trial.
  • Used BloodFlow to evaluate peripheral residual disease in large blood volumes and mass spectrometry in serum samples.
  • Conducted periodic assessments of PRD and MRD using next-generation flow.
  • 32 (13%) of patients had detectable circulating tumor cells and an increased risk of disease progression.
  • Median progression-free survival was not reached in PRD-negative patients compared to 2 months in PRD-positive patients.
  • Concordance between PRD and MRD was 84%, highlighting the efficacy of BloodFlow in assessing disease status.

Cite This Study

Romero et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc89https://doi.org/10.1182/blood-2025-919
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study2025
  2. 2Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma2024 · 17 citations
  3. 3Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)2025
  4. 4Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 1 citations
  5. 5Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025